Product Description
The Australia Dental Bone Graft Substitutes (DBGS) and other biomaterials market was valued at nearly $30 million in 2024. This is expected to increase over the forecast period at a CAGR of 11% to reach over $61 million.
The full report suite on the Australian market for dental bone graft substitutes (DBGSs) and other biomaterials includes DBGSs, dental barrier membranes, local antimicrobial periodontal treatments and dental soft tissue wound care. Collectively, these segments will be referred to as the dental biomaterials market.
MARKET REPORT DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2031, and Historical Data to 2021
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
AUSTRALIA DENTAL BONE GRAFT SUBSTITUTES MARKET TRENDS

A notable trend in the Australian dental biomaterials market is the growing adoption of allografts. Historically, allografts have encountered regulatory challenges in gaining approval. However, rising demand from dental professionals, coupled with gradual improvements in the regulatory approval process, is expected to support increased market penetration and drive growth in this segment over the forecast period.
AUSTRALIA DENTAL BONE GRAFT SUBSTITUTES MARKET SHARE INSIGHTS

- Geistlich led the dental biomaterials market in Australia in 2024, driven by its dominance in the xenograft segment. Its flagship Bio-Oss® bovine xenograft line remained the gold standard, and the 2020 addition of a 50 mg Bio-Oss® Collagen variant supported use in narrow defects and minor augmentations. Geistlich’s strong market presence is also supported by the Bio-Gide® collagen membrane, which continues to lead the dental barrier membrane segment. Widespread familiarity with Geistlich products among Australian dentists, stemming from early exposure in dental school, has reinforced its brand strength. However, economic pressures have caused some clinicians to consider lower-cost alternatives or companies with broader portfolios. Despite this, Geistlich is expected to retain its leadership position in the DBGS market over the forecast period.
- Australian Biotechnologies achieved a strong market share through the budding allograft market in Australia. The company’s Oravance™ brand is very popular in the country, where regulatory barriers have reduced competitive pressure from other producers. The products are particularly popular in the hospital setting and are set to drive growth in the allograft market.
- Henry Schein reinforced its presence in the Asia-Pacific dental market in 2024, driven by the sustained growth of its subsidiary, BioHorizons. BioHorizons has demonstrated strong performance in the region, particularly in Australia, where it ranked third in the dental biomaterials market. Its portfolio of DBGS products includes MinerOss®, Grafton® DBM and LADDEC®, all originally developed by Osteotech. The MinerOss® line features cortical, cancellous and composite allograft options. While BioHorizons is categorized as a mid-sized competitor, it has exhibited notable expansion in both dental implant and regenerative product segments, contributing significantly to Henry Schein’s broader strategic presence across Asia-Pacific.
AUSTRALIA DENTAL BONE GRAFT SUBSTITUTES MARKET SEGMENTATION SUMMARY
- Dental Bone Graft Substitute (DBGS) Market – Further Segmented Into:
- Application: Socket Preservation, Sinus Augmentation, Ridge Augmentation, and Periodontal.
- Type: Mineralized Allograft, Demineralized Bone Matrix (DBM) Allograft, Xenograft, and Synthetic.
- Dental Barrier Membrane – Further Segmented Into:
- Type: Resorbable, and Non-Resorbable.
- Material: Xenograft, Synthetic, and Allograft.
- Antimicrobial Periodontal Treatment
- Dental Soft Tissue Wound Care – Further Segmented Into:
- Type: Plugs, Tape, and Foam.
*Segment is analyzed at a unit level only.
GLOBAL RESEARCH SCOPE
| Report Attribute | Details |
|---|---|
| Region | Asia Pacific (Australia) |
| Base Year | 2024 |
| Forecast | 2025-2031 |
| Historical Data | 2021-2023 |
| Quantitative Coverage | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.